Prøve GULL - Gratis
"India needs vaccines that are 'Made for India"
Bio Spectrum
|BioSpectrum India Jan 2025
With a legacy of over 75 years in pioneering advancements with their vaccines within the Indian pharmaceutical landscape, Mumbai-based Novo Medi Sciences (Novo Group) has been instrumental in introducing many first-of-itskind vaccines in India, playing a vital role in public health and setting standards in healthcare quality and accessibility.
-
The company is all set to launch new vaccines in the country, further strengthening the innovation landscape for vaccine R&D. Forum Bhagat, Managing Director of Novo Medi Sciences (Novo Group) spoke to BioSpectrum about the company's present and future plans. Edited excerpts:
What were the key highlights of the company in 2024? What are the major plans in store for 2025?
In 2024, we continued to expand our mission, considering that we must cater to critical healthcare challenges with innovative solutions. One of our recent key achievements, guided by the principles of our founder and my grandfather, late Ramesh C Bhagat, was the reintroduction of NEXICLOX DS 250mg, a trusted Cloxacillin syrup formulation.
This move addresses the dire need for effective treatments against critical infections like skin and soft tissue infections (SSTIs), osteomyelitis, respiratory tract infections (RTIs), and Endocarditis within the paediatric community. Initially launched in 1965, Cloxacillin is the gold-standard penicillin that was discontinued in the Indian pharmaceutical market for over 25 years. The rise of multi-drug resistance (MDR) has rendered many current combination molecules ineffective against susceptible Staphylococcus infections. Consequently, the medical fraternity emphasised the need for 'old is gold' standard molecules like Cloxacillin, which offers a lower likelihood of resistance due to its limited use in recent years.
By reintroducing NEXICLOX DS 250mg, we aim to provide healthcare professionals with a reliable and effective solution for treating critical infections in children, effective against MDR methicillin-susceptible Staphylococcus Aureus (MSSA) and has a low resistance risk with a proven safety profile.
Denne historien er fra BioSpectrum India Jan 2025-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Bio Spectrum
Supporting India's Biopharma Expansion with Advanced, High-Performance Media
Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.
4 mins
December 2025
Bio Spectrum
Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging
Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.
1 min
December 2025
Listen
Translate
Change font size